Semaglutide UK 2026 Research Reference: STEP, SUSTAIN, SELECT and FLOW Trial Data, Mechanism and Protocol Design

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

Table of Contents

• 1. What semaglutide is — molecular and pharmacological framing
• 2. Mechanism of action — single GLP-1 agonism
• 3. STEP programme — obesity
• 4. SUSTAIN programme — type 2 diabetes
• 5. SELECT — cardiovascular outcomes
• 6. FLOW — diabetic kidney disease
• 7. STEP-TEENS — adolescent obesity
• 8. PIONEER — oral semaglutide
• 9. MASLD and MASH research signals
• 10. Mechanism beyond weight — neuroprotection, addiction, inflammation
• 11. Safety profile summary
• 12. Semaglutide vs tirzepatide vs retatrutide
• 13. UK laboratory research protocol design
• 14. Frequently asked questions
• 15. References

1. What semaglutide is — molecular and pharmacological framing

Semaglutide is a synthetic peptide analogue of human glucagon-like peptide 1 (GLP-1), modified to resist degradation by dipeptidyl peptidase 4 (DPP-4) and to bind albumin for extended half-life. The molecule is structurally derived from native GLP-1 with two amino acid substitutions (at positions 8 and 34) and a C18 fatty acid chain attached via a spacer at position 26 enabling albumin binding.

This modification gives semaglutide a terminal half-life of approximately 7 days, supporting once-weekly dosing for subcutaneous formulations. An oral tablet formulation (Rybelsus) uses absorption-enhancer technology (SNAC, sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) to achieve adequate bioavailability for daily oral administration.

2. Mechanism of action — single GLP-1 agonism

Semaglutide activates the GLP-1 receptor (GLP-1R) — a G-protein-coupled receptor expressed in pancreatic beta cells, alpha cells, enteroendocrine cells, CNS (hypothalamus, brainstem), cardiovascular tissue, and multiple other tissues. Key physiological effects:

• Glucose-dependent insulin secretion — amplifies the beta-cell response to elevated blood glucose
• Glucagon suppression — reduces hepatic glucose output
• Gastric emptying delay — slows postprandial glucose absorption
• CNS satiety signalling — reduces appetite and food intake via hypothalamic and brainstem GLP-1R
• Cardiovascular effects — endothelial function, blood pressure reduction, inflammation modulation
• Renal effects — tubular protection, glomerular haemodynamics modulation

Unlike tirzepatide (dual GLP-1/GIP) and retatrutide (triple GLP-1/GIP/glucagon), semaglutide is a pure GLP-1 receptor agonist — its mechanism is mono-axial. This provides a clean reference for mechanistic research on GLP-1R-specific biology.

3. STEP programme — obesity

The STEP (Semaglutide Treatment Effect in People with Obesity) programme established semaglutide 2.4 mg weekly as a treatment for obesity:

• STEP-1 (2021): 1,961 adults with BMI ≥ 30 (or ≥ 27 with comorbidity), non-diabetic. Semaglutide 2.4 mg vs placebo. Mean weight change at 68 weeks: −14.9% (semaglutide) vs −2.4% (placebo). Placebo-adjusted: −12.4%.
• STEP-2: T2DM population; smaller weight loss (~10%) but meaningful HbA1c improvement.
• STEP-3: semaglutide + intensive behavioural therapy; weight loss −16%.
• STEP-4: weight maintenance after initial semaglutide treatment; continued semaglutide → continued weight loss; placebo switch → weight regain.
• STEP-5: 104-week (2-year) extension; weight loss sustained.
• STEP-8: semaglutide 2.4 mg vs liraglutide 3.0 mg head-to-head — semaglutide superior (−15.8% vs −6.4%).

STEP established the benchmark for GLP-1-class weight loss efficacy prior to tirzepatide’s SURMOUNT-1.

4. SUSTAIN programme — type 2 diabetes

The SUSTAIN (Semaglutide Unabated Sustainability in Type 2 Diabetes) programme evaluated semaglutide 0.5 mg and 1.0 mg weekly in T2DM:

• SUSTAIN-6 (CVOT): 3,297 adults with T2DM and established CVD. Primary endpoint: MACE. Result: 26% reduction with semaglutide vs placebo.
• SUSTAIN-1 through 5 and 7 through 10: efficacy comparisons vs placebo, other GLP-1 agonists, insulin, and DPP-4 inhibitors. Semaglutide consistently produced superior HbA1c reduction (1.5-1.8%) and weight loss.

SUSTAIN-6 was a landmark cardiovascular outcomes trial establishing GLP-1-class cardioprotection in T2DM.

5. SELECT — cardiovascular outcomes

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) — Lincoff et al., NEJM 2023:

• 17,604 adults with BMI ≥ 27 and established CVD, no diabetes
• Semaglutide 2.4 mg weekly vs placebo
• Primary endpoint: MACE (CV death, non-fatal MI, non-fatal stroke)
• Result: 20% relative risk reduction in MACE (HR 0.80; 95% CI 0.72-0.90)
• Mean weight loss: 9.4% (semaglutide) vs 0.9% (placebo)

SELECT was the first CVOT to demonstrate cardiovascular risk reduction with a weight-loss medication in adults without diabetes — a landmark finding establishing obesity itself as a modifiable cardiovascular risk factor.

6. FLOW — diabetic kidney disease

FLOW (A Research Study to See How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease) — Perkovic et al., NEJM 2024:

• 3,533 adults with T2DM and CKD
• Semaglutide 1.0 mg weekly vs placebo
• Primary endpoint: composite of kidney failure, sustained eGFR decline ≥ 50%, renal death, or CV death
• Result: 24% relative risk reduction in primary outcome

FLOW established renal protection as a semaglutide benefit alongside cardiovascular and metabolic effects.

7. STEP-TEENS — adolescent obesity

STEP-TEENS (Weghuber et al., NEJM 2022) — 201 adolescents (12-17 years) with obesity, randomised to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight loss: −16.1% (semaglutide) vs +0.6% (placebo), placebo-adjusted −16.7%. Supported regulatory approval for adolescent use in multiple jurisdictions.

8. PIONEER — oral semaglutide

The PIONEER programme evaluated oral semaglutide (Rybelsus, formulated with SNAC absorption-enhancer technology):

• Doses: 3, 7, 14 mg daily oral
• Efficacy: HbA1c reduction 1.0-1.4% at 14 mg dose (comparable to subcutaneous formulations at lower-mid doses)
• PIONEER-6 CVOT: cardiovascular safety confirmed (non-inferiority design)

Oral semaglutide was the first orally-active GLP-1 receptor agonist approved for T2DM.

9. MASLD and MASH research signals

Semaglutide in MASLD / MASH:

• Newsome et al., NEJM 2021: semaglutide 0.4 mg daily in MASH — significantly higher rate of NASH resolution (59% vs 17% placebo)
• Liver fat reduction of approximately 30-40% in broader MASLD studies
• Effects on liver fibrosis more modest than on inflammation resolution

Semaglutide’s hepatic effects are substantial but less pronounced than tirzepatide’s or retatrutide’s in head-to-head or cross-trial comparisons.

10. Mechanism beyond weight — neuroprotection, addiction, inflammation

Emerging research areas:

• Alzheimer’s / neuroprotection: semaglutide is under investigation for cognitive decline in early Alzheimer’s (EVOKE and EVOKE+ trials)
• Addiction research: preclinical and clinical observations suggest reduced alcohol and nicotine consumption; trials exploring GLP-1-class role in substance use disorders
• Inflammation and immunometabolism: semaglutide appears to modulate systemic inflammation markers beyond what weight loss alone would explain

11. Safety profile summary

Most common adverse events (STEP, SUSTAIN, SELECT):

• Nausea (40-45% at 2.4 mg, vs placebo 10-15%)
• Vomiting (20-25%)
• Diarrhoea (25-30%)
• Constipation (15-20%)
• Discontinuation due to AE: ~7% across major trials
• Hypoglycaemia rare in monotherapy; more common with insulin/sulfonylurea combinations
• Heart rate: +3-4 bpm modest elevation
• Thyroid C-cell class caution (rodent data; human epidemiological evidence limited)

12. Semaglutide vs tirzepatide vs retatrutide

Positioning at maximum approved or studied doses:

• Semaglutide 2.4 mg (STEP-1, 68 weeks): −14.9% weight loss; −12.4% placebo-adjusted
• Tirzepatide 15 mg (SURMOUNT-1, 72 weeks): −22.5% weight loss; −17.8% placebo-adjusted
• Retatrutide 12 mg (Phase 2, 48 weeks, still trending): −24.2% weight loss

Semaglutide is the established benchmark with the deepest clinical evidence base (STEP, SUSTAIN, SELECT, FLOW), but is surpassed on efficacy by the newer dual and triple agonists. It remains the dominant GLP-1-class molecule in clinical practice globally.

13. UK laboratory research protocol design

For UK laboratory semaglutide research:

• Purity: ≥ 98% HPLC (≥ 99% emerging 2026 standard)
• Identity: MS confirmation per batch
• Format: lyophilised with batch-specific COA
• Reconstitution: bacteriostatic water (typical concentrations 1-5 mg/ml)
• Storage: lyophilised at 2-8°C or −20°C; reconstituted at 2-8°C for up to 28 days
• Dosing in rodent models: dose-scaling from human 2.4 mg/week is not straightforward; consult published preclinical references for specific models
• Comparator design: semaglutide is the reference molecule for cross-GLP-1 comparator studies

See our Research-Grade Peptides Guide for standards detail and GLP-1 Peptides UK Complete 2026 Research Reference for class context.

14. Frequently asked questions

Is semaglutide the same as Ozempic and Wegovy?

Yes. Semaglutide is the active ingredient; Ozempic is the T2DM brand (0.25-2 mg doses), Wegovy is the obesity brand (up to 2.4 mg), and Rybelsus is the oral T2DM formulation.

What is the weight loss outcome with semaglutide in STEP-1?

Mean weight loss of 14.9% at 68 weeks with semaglutide 2.4 mg weekly, vs 2.4% with placebo. Placebo-adjusted: 12.4%.

What did SELECT show?

A 20% relative risk reduction in major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke) in adults with obesity and established CVD, no diabetes. Landmark finding establishing obesity as modifiable CV risk.

How often is semaglutide dosed?

Subcutaneous: once weekly. Oral (Rybelsus): once daily with morning water and fasting window before food.

What is semaglutide’s half-life?

Approximately 7 days — the longest half-life of major GLP-1-class molecules, supporting convenient weekly dosing.

How does semaglutide compare to tirzepatide?

In SURPASS-2 (head-to-head in T2DM), tirzepatide 15 mg produced greater HbA1c and weight reduction than semaglutide 1 mg. At maximum doses across cross-trial comparisons, tirzepatide 15 mg produces approximately 50% more weight loss than semaglutide 2.4 mg.

Can semaglutide be used in MASLD research?

Yes. Semaglutide has Phase 2 evidence in MASH (Newsome 2021) with NASH resolution at 59%. It’s an established comparator molecule for MASLD/MASH research, though newer molecules (tirzepatide, retatrutide) show larger hepatic effect sizes.

15. References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002. (STEP-1)
2. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-1844. (SUSTAIN-6)
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232. (SELECT)
4. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121. (FLOW)
5. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med 2022;387:2245-2257. (STEP-TEENS)
6. Rubino DM, Greenway FL, Khalid U, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA 2022;325(14):1414-1425. (STEP-4)
7. Rubino DM, Abrahamsson N, Davies M, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight. JAMA 2022;327(2):138-150. (STEP-8)
8. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 2021;384:1113-1124.
9. Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2019;381:841-851. (PIONEER-6)
10. Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017;377:839-848. (class context)

UK Research Cluster Hubs

• GLP-1 Peptides Complete Research Reference
• Retatrutide UK Research Guide
• Tirzepatide UK Research Guide
• BPC-157 UK Research Guide
• TB-500 UK Research Guide
• Research-Grade Peptides Standards Guide
• UK Research Peptide Buying Guide

Disclaimer: Semaglutide is a prescription medication approved for specific clinical indications. Research-grade semaglutide supplied by Peptides Lab UK is for licensed in vitro and ex vivo laboratory research purposes only. Not for human consumption, veterinary use, or any therapeutic application.